7MM PAH diagnosed cases to fall to 76,035 by 2034

The projection represents a negative annual growth rate of 0.08%.

The total number of diagnosed prevalent cases of pulmonary arterial hypertension (PAH) across the seven major markets (7MM) is projected to decline from 76,645 in 2024 to 76,035 in 2034, according to GlobalData.

The projection represents a negative annual growth rate of 0.08%.

Amongst these markets, the US is expected to report the highest number of diagnosed prevalent cases in 2034, at 29,591.

In contrast, the UK is projected to have the lowest number of cases, with 3,773.

“In the past decade, there have been major advances in the understanding of the mechanism of disease development, diagnostic process, and treatment of PAH,” said Bharti Prabhakar, MPH, Associate Project Manager, Epidemiology at GlobalData.

However, the condition continues to be diagnosed late in many patients, often when hemodynamic complications have already progressed, Prabhakar added.

7MM = US, Germany, France, Italy, Spain, UK, and Japan.